Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: methotrexate

Ethics Forum: Mitigation Tips for Health Disparities Among Rural & Indigenous Peoples

Laura Nichols, MD, Lee Graham, MD, & Erdal Diri, MD  |  October 12, 2023

A common case scenario in our practice in North Dakota is a woman with rheumatoid arthritis on methotrexate monotherapy. She is a member of the Sisseton Wahpeton Oyate people and lives 90 miles from our rheumatology clinic. She currently has moderate disease activity, indicating the need for additional treatment. She does not have her own…

Filed under:EthicsGuidancePractice Support Tagged with:DisparitiesEthics Forumhealth disparitiesrural rheumatologytelemedicine

In Memoriam: Remembering Frederick Wolfe, MD

Theodore Pincus, MD, & Kaleb Michaud, PhD  |  October 3, 2023

Rheumatology giant Frederick Wolfe, MD, passed away Sept. 5, 2023, in Wichita, Kan. The rheumatology community mourns his loss. Fred was born July 1, 1936, in New York. He graduated from Queens College, N.Y., in 1958, and was a social worker for several years. He earned his medical degree in 1966 from the State University…

Filed under:OpinionProfiles

Investigational Nanobody Compound Shows Promise for RA Treatment

Michele B. Kaufman, PharmD, BCGP  |  September 14, 2023

In Japan, ozoralizumab will soon be available as a 30 mg subcutaneous auto-injection to treat patients with rheumatoid arthritis.

Filed under:Biologics/DMARDsDrug Updates Tagged with:anti-TNF agent

Ignite the Spark of Joy & Discovery

Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS  |  September 9, 2023

A Roshi (i.e., master) apparently said that in Zen, “there is nothing to believe and everything to discover.” Interestingly enough, I have never been able to confirm who actually said that, which makes this saying about belief and discovery particularly apt. Regardless, I think about those words at least twice a day when I am…

Filed under:Career DevelopmentEducation & TrainingOpinionProfessional TopicsRheuminations

A Novel Study Compared the Effectiveness of Adalimumab with Tofacitinib in RA

Samantha C. Shapiro, MD  |  August 17, 2023

Your patient with rheumatoid arthritis (RA) isn’t responding well enough to methotrexate, and you both agree it’s time to consider a biologic or targeted synthetic disease-modifying anti-rheumatic drug (DMARD). But which one should you choose? In a treat-to-target era, we’re fortunate to have a variety of RA therapies at our disposal. Clinical practice guidelines from…

Filed under:Biologics/DMARDsConditionsDrug UpdatesRheumatoid Arthritis Tagged with:adalimumabDisease-modifying antirheumatic drugs (DMARDs)Rheumatoid Arthritis (RA)Tofacitinib

Guideline for Integrative RA Interventions Released

Ruth Jessen Hickman, MD  |  August 3, 2023

Discussions between clinicians and their patients about complementary aspects of their care just got easier with the release of the 2022 ACR Guideline for Exercise, Rehabilitation, Diet, and Additional Integrative Interventions for Rheumatoid Arthritis.

Filed under:American College of RheumatologyClinical Criteria/GuidelinesConditionsGuidanceGuidelinesRheumatoid Arthritis Tagged with:RA Resource Center

Measuring Up: A Review of the ACR-Owned Quality Measures

Allison Plitman, MPA  |  July 25, 2023

Since 2006, the Centers for Medicaid & Medicare Services (CMS) has increasingly driven clinicians to focus on and improve quality. Quality measures help clinicians measure how well they treat their patients. By tracking their performance, clinicians can identify opportunities to improve patient care while meeting federal reporting requirements. Breaking Down Quality Measures The CMS has…

Filed under:Uncategorized

A Dual Inhibitor Treatment for RA?

Michele B. Kaufman, PharmD, BCGP  |  July 17, 2023

TLL-018, a Janus kinase 1/tyrosine kinase 2 inhibitor, proved more effective for treating patients with RA than tofacitinib, according to a study by Zeng et al.

Filed under:Biologics/DMARDsDrug UpdatesMeeting Reports Tagged with:EULAR 2023

How to Discuss Anti-Inflammatory Diets & Supplements with Your Patients

Emily Molina, MD  |  June 9, 2023

My patients ask me almost daily what kind of diet they should be on, or if there are certain supplements they should try. And a growing amount of evidence shows lifestyle and dietary factors may contribute to disease risk and outcomes in rheumatic disease. Thus, rheumatologists and rheumatology professionals are being called upon by patients…

Filed under:ConditionsHome SliderPatient Perspective Tagged with:Dietdietary supplementpatient communication

In the Wake of Dobbs v. Jackson Women’s Health Organization

Mary Beth Nierengarten  |  May 10, 2023

Since the Supreme Court ruling in June 2022 overturning 50 years of precedent protecting abortion as a constitutional right (Dobbs v. Jackson Women’s Health Organization), states are enacting and implementing new laws to regulate abortion, and medical organizations and healthcare providers are assuming the large task of understanding what the new laws mean for their…

Filed under:EthicsLegal UpdatesProfessional Topics Tagged with:abortionDobbs v. Jackson Women's Health Organization

  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 105
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences